Free tool
FAERS Monitor: Jeuveau
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761085 or its brand name (Jeuveau, Prabotulinumtoxina-Xvfs). Reports on generic versions are filed under their own applications.
Reports
3,779
Serious
61
2% of reports
Hospitalization
24
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,590
- off label use1,315
- therapeutic product effect decreased715
- drug effect less than expected469
- headache171
- injection site pain114
- patient dissatisfaction with treatment105
- injection site swelling99
- eyelid ptosis73
- inappropriate schedule of product administration72
- injection site erythema67
- product preparation issue59
- injection site pruritus52
- dizziness45
- vision blurred43
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 1,156 |
| 2020 | 749 |
| 2021 | 199 |
| 2022 | 175 |
| 2023 | 273 |
| 2024 | 326 |
| 2025 | 406 |
| 2026 | 495 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,380 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| patient dissatisfaction with treatmentSignal | 105 | 320.7 | 264.1 | 31,340 |
| drug effect less than expectedSignal | 469 | 181.9 | 166.8 | 81,580 |
| therapeutic product effect decreasedSignal | 715 | 90.3 | 84.5 | 62,160 |
| product preparation issueSignal | 59 | 50.5 | 39.2 | 2,789 |
| eyelid ptosisSignal | 73 | 40.3 | 32.1 | 2,738 |
| off label useSignal | 1,315 | 8.4 | 8.0 | 8,883 |
| injection site swellingSignal | 99 | 7.2 | 5.9 | 524 |
| drug ineffectiveSignal | 1,590 | 6.7 | 6.5 | 8,246 |
| injection site pruritusSignal | 52 | 4.3 | 3.3 | 130 |
| injection site erythemaSignal | 67 | 3.0 | 2.4 | 88 |
| inappropriate schedule of product administrationSignal | 72 | 2.2 | 1.8 | 48 |
| injection site painSignal | 114 | 2.1 | 1.7 | 63 |
| vision blurred | 43 | 1.7 | 1.3 | 13 |
| headache | 171 | 1.5 | 1.3 | 31 |
| dizziness | 45 | 0.5 | 0.4 | 22 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.